18 Analysts Have This to Say About Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
18 analysts have rated Regeneron Pharmaceuticals (NASDAQ:REGN) over the past 3 months, with an average price target of $897.5, up 6.09% from the previous average of $846. The current price of REGN is $749.44.
June 09, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals (REGN) has an average price target of $897.5 from 18 analysts, up 6.09% from the previous average. Current price is $749.44.
The average price target of $897.5 for Regeneron Pharmaceuticals (REGN) from 18 analysts indicates a potential upside from the current price of $749.44. The increase of 6.09% from the previous average price target suggests growing optimism among analysts, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100